4512 WAKAMOTO PHARMACEUTICAL
- 246
- +7+2.93%
WAKAMOTO PHARMACEUTICAL News
Wakamoto Pharmaceutical FY Parent Net Y108.00M Vs Net Y138.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Year Ended March 31 PARENT 2024 2023 Revenue Y7.74 bln Y8.66 bln Operating Profit (Y1
WAKAMOTO PHARMACEUTICAL: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (unconsolidated)
Open H, Mitsui Chemicals, Mitsubishi Chemical G, WOWOW (15 days) (1380-4990)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/15 (Wed) ＜1380＞Akigawa Pasture ＜1446＞Candyle＜1447＞itbookHD ＜145A＞ELISBE＜148A＞Hatch Work ＜149A＞Shinka ＜150A＞JSH ＜1514＞Residence
Wakamoat Pharmaceutical Issues FY Dividend Plan at Y3.00
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) PARENT Latest Revision Previous For Year to Mar 2024 Plan Year-end Y3.00 N/A Annual Y3.00
Wakamoto Pharmaceutical Sees FY Parent Pretax Loss Y80.00M
PARENT New Forecast For Year to Mar 2024 Revenue Y7.80 bln Operating Profit (Y120.00 mln) Pretax Profit (Y80.00 mln)
Wakamoto Pharmaceutical 1H Parent Loss Y222.00M Vs Loss Y21.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan 1st Half Ended September 30 PARENT 2023 2022 Revenue Y3.62 bln Y4.02 bln Operating Pro
Wakamoto Pharmaceutical 1Q Parent Net Y100.00M Vs Loss Y4.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan 1st Quarter Ended June 30 PARENT 2023 2022 Revenue Y1.86 bln Y2.02 bln Operating Profit
Wakamoto Pharmaceutical FY Parent Net Y138.00M Vs Net Y238.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Year Ended March 31 PARENT 2023 2022 Revenue Y8.66 bln Y8.38 bln Operating Profit
Wakamoto Pharmaceutical 9-Mos Parent Net Y110.00M Vs Net Y210.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Nine Months Ended December 31 PARENT 2022 2021 Revenue Y6.27 bln Y6.27 bln Operating
Analysis
Price Target
No Data
